Gemini Therapeutics, Inc. (NASDAQ:GMTX - Get Free Report) shares reached a new 52-week high during trading on Monday . The stock traded as high as $32.55 and last traded at $30.52, with a volume of 387330 shares traded. The stock had previously closed at $31.83.
Gemini Therapeutics Stock Down 4.1 %
The company has a 50 day simple moving average of $59.12 and a two-hundred day simple moving average of $55.72. The company has a market capitalization of $1.32 billion, a P/E ratio of -1.35 and a beta of -0.12.
Hedge Funds Weigh In On Gemini Therapeutics
Several large investors have recently modified their holdings of GMTX. Virtu Financial LLC bought a new position in Gemini Therapeutics during the 2nd quarter valued at about $35,000. Goldman Sachs Group Inc. grew its stake in shares of Gemini Therapeutics by 80.1% during the second quarter. Goldman Sachs Group Inc. now owns 36,635 shares of the company's stock valued at $62,000 after buying an additional 16,297 shares during the last quarter. UBS Group AG bought a new stake in shares of Gemini Therapeutics during the 2nd quarter worth approximately $234,000. Bank of Montreal Can bought a new stake in shares of Gemini Therapeutics during the 2nd quarter worth approximately $276,000. Finally, Renaissance Technologies LLC boosted its holdings in Gemini Therapeutics by 2,850.4% during the 1st quarter. Renaissance Technologies LLC now owns 351,100 shares of the company's stock valued at $488,000 after acquiring an additional 339,200 shares during the period. Institutional investors own 75.42% of the company's stock.
About Gemini Therapeutics
(
Get Free Report)
Gemini Therapeutics, Inc, a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Gemini Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gemini Therapeutics wasn't on the list.
While Gemini Therapeutics currently has a "hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.
Get This Free Report
